Stryker (SYK) in Fundsmith 2024 Q2

Advancing in Medical Technology and Innovation

Author's Avatar
Apr 15, 2025
Summary
  • Strong growth in medical devices and technology solutions.
  • Leadership in orthopedics and surgical equipment.
  • Risks include regulatory hurdles and competitive market dynamics.
  • Contributed 0.8% to Fundsmith's performance in the first half of 2024.
  • Future outlook is promising with continued innovation in healthcare solutions.

Stryker (SYK, Financial) was highlighted in the Fundsmith 2024 Q2 letter as a positive contributor to the fund's performance. The company's focus on medical technology and innovation has driven its growth in the healthcare sector.

"Stryker's advancements in medical devices and technology have been instrumental in our fund's performance, contributing 0.8% in the first half of 2024." — Terry Smith, Fundsmith LLP, Q2 2024 Fund Letter

Read full letter at gurufocus Fundsmith 2024 Q2 page.